X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (128) 128
female (51) 51
male (50) 50
middle aged (47) 47
aged (46) 46
adult (39) 39
hematology (37) 37
anticoagulants (35) 35
peripheral vascular disease (32) 32
thromboembolism (31) 31
anticoagulants - therapeutic use (30) 30
double-blind method (30) 30
venous thromboembolism (30) 30
prevention (29) 29
thrombosis (29) 29
surgery (27) 27
treatment outcome (27) 27
medicine, general & internal (26) 26
aged, 80 and over (25) 25
enoxaparin (24) 24
anticoagulants - administration & dosage (22) 22
thromboembolism - prevention & control (22) 22
hemorrhage - chemically induced (21) 21
clinical trials as topic (20) 20
heparin (20) 20
index medicus (20) 20
postoperative complications - prevention & control (19) 19
deep-vein thrombosis (17) 17
fibrinolytic agents - therapeutic use (17) 17
time factors (17) 17
venous thrombosis - prevention & control (17) 17
administration, oral (16) 16
anticoagulants - adverse effects (16) 16
drug therapy (16) 16
warfarin (16) 16
heparin - therapeutic use (15) 15
molecular-weight heparin (15) 15
prophylaxis (15) 15
cardiac & cardiovascular systems (14) 14
randomized controlled trials as topic (14) 14
risk factors (14) 14
clinical trials (13) 13
double-blind (13) 13
fibrinolytic agents - administration & dosage (13) 13
stroke (13) 13
thrombophlebitis - prevention & control (13) 13
drug administration schedule (12) 12
evaluation (12) 12
fibrinolytic agents - adverse effects (12) 12
health aspects (12) 12
pulmonary embolism - prevention & control (12) 12
risk (12) 12
rivaroxaban (12) 12
thromboprophylaxis (12) 12
venous thrombosis (12) 12
aspirin (11) 11
dose-response relationship, drug (11) 11
heparin, low-molecular-weight - administration & dosage (11) 11
thromboembolism - etiology (11) 11
aspirin - therapeutic use (10) 10
enoxaparin - therapeutic use (10) 10
factor xa inhibitors (10) 10
heparin, low-molecular-weight - therapeutic use (10) 10
injections, subcutaneous (10) 10
prospective studies (10) 10
unfractionated heparin (10) 10
venous thromboembolism - prevention & control (10) 10
enoxaparin - administration & dosage (9) 9
enoxaparin - adverse effects (9) 9
platelet aggregation inhibitors - therapeutic use (9) 9
adolescent (8) 8
arthroplasty (8) 8
care and treatment (8) 8
drug therapy, combination (8) 8
follow-up studies (8) 8
heparin - administration & dosage (8) 8
metaanalysis (8) 8
pulmonary embolism - drug therapy (8) 8
pulmonary-embolism (8) 8
replacement (8) 8
analysis (7) 7
animals (7) 7
anticoagulant (7) 7
arthroplasty, replacement, knee - adverse effects (7) 7
atrial fibrillation (7) 7
blood platelets - drug effects (7) 7
dosage and administration (7) 7
fondaparinux (7) 7
heart valve prosthesis (7) 7
incidence (7) 7
management (7) 7
medical research (7) 7
phlebography (7) 7
random allocation (7) 7
randomized trial (7) 7
thrombolytic therapy (7) 7
thrombophlebitis - drug therapy (7) 7
total hip-replacement (7) 7
trial (7) 7
venous thrombosis - drug therapy (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Plos One, ISSN 1932-6203, 2013, Volume 8, Issue 5, p. e63479
Journal Article
European Heart Journal, ISSN 0195-668X, 08/2017, Volume 38, Issue suppl_1
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 11/2005, Volume 3, Issue 11, pp. 2479 - 2486
Background: BAY 59‐7939, a novel, oral, direct factor Xa inhibitor, is in clinical development for the prevention of venous thromboembolism (VTE), a frequent... 
total knee replacement | prophylaxis | direct Factor Xa inhibitor | oral anticoagulant | venous thromboembolism | Direct factor Xa inhibitor | Oral anticoagulant | Total knee replacement | Venous thromboembolism | Prophylaxis | ENOXAPARIN | SURGERY | XIMELAGATRAN | TRIALS | DIRECT THROMBIN INHIBITOR | TOLERANCE | DEEP-VEIN THROMBOSIS | LEG | TOTAL HIP | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Thiophenes - therapeutic use | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Thromboembolism - epidemiology | Enoxaparin - adverse effects | Incidence | Rivaroxaban | Enoxaparin - administration & dosage | Thromboembolism - prevention & control | Hemorrhage - etiology | Injections, Subcutaneous | Aged, 80 and over | Adult | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Antithrombin III - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Administration, Oral | Morpholines - administration & dosage | Antithrombin III - therapeutic use | Anticoagulants - therapeutic use | Antithrombin III - administration & dosage | Thromboembolism - etiology | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Venous Thrombosis - epidemiology | Aged
Journal Article
Journal Article
Journal Article
Heart, ISSN 1355-6037, 02/2017, Volume 103, Issue 4, pp. 307 - 314
Journal Article
Circulation, ISSN 0009-7322, 09/2004, Volume 110, Issue 12, pp. 1658 - 1663
Background-When warfarin is interrupted for surgery, low-molecular-weight heparin is often used as bridging therapy. However, this practice has never been... 
Blood vessel prosthesis | Fibrillation | Heparin | Low-molecular-weight | Bridging therapy | ENOXAPARIN | SURGERY | CARDIAC & CARDIOVASCULAR SYSTEMS | PERIOPERATIVE MANAGEMENT | THROMBOSIS | bridging therapy | ACUTE CORONARY SYNDROMES | blood vessel prosthesis | ASPIRIN | COUMADIN | ANTICOAGULATION | PROSTHETIC HEART-VALVES | heparin, low-molecular-weight | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | fibrillation | Dalteparin - administration & dosage | Heart Valve Prosthesis Implantation | Prospective Studies | Anticoagulants - administration & dosage | Humans | Postoperative Complications - prevention & control | Postoperative Hemorrhage - chemically induced | Risk | Thromboembolism - epidemiology | Warfarin - administration & dosage | Aspirin - administration & dosage | Feasibility Studies | Blood Loss, Surgical | Dalteparin - therapeutic use | Thromboembolism - prevention & control | Vitamin K - administration & dosage | Intraoperative Complications - epidemiology | Arterial Occlusive Diseases - epidemiology | Dalteparin - adverse effects | Intraoperative Complications - prevention & control | Anticoagulants - therapeutic use | Treatment Outcome | Postoperative Complications - epidemiology | Anticoagulants - adverse effects | Atrial Fibrillation - surgery | Preoperative Care | International Normalized Ratio | Arterial Occlusive Diseases - prevention & control | Elective Surgical Procedures | Cohort Studies | Premedication
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 06/2006, Volume 4, Issue 6, pp. 1246 - 1252
Journal Article
Journal Article
European Heart Journal, ISSN 0195-668X, 08/2017, Volume 38, Issue suppl_1
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 10/2017, Volume 15, Issue 10, pp. 1913 - 1922
Essentials Anticoagulants prevent venous thromboembolism but may be associated with greater bleeding risks. Bivariate analysis assumes a non‐linear... 
anticoagulant | clinical efficacy | adverse drug reaction | venous thromboembolism | hemorrhage | ENOXAPARIN | METAANALYSIS | RIVAROXABAN | PREVENTION | DEEP-VEIN THROMBOSIS | ATRIAL-FIBRILLATION | PROPHYLAXIS | BETRIXABAN | WARFARIN | CLINICAL-TRIALS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Multivariate Analysis | Anticoagulants - administration & dosage | Humans | Enoxaparin - adverse effects | Rivaroxaban - administration & dosage | Venous Thromboembolism - blood | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Benzamides - administration & dosage | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Rivaroxaban - adverse effects | Time Factors | Clinical Decision-Making | Benzamides - adverse effects | Pyrazoles - adverse effects | Venous Thromboembolism - diagnosis | Acute Disease | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Risk Factors | Treatment Outcome | Hospitalization | Anticoagulants - adverse effects | Clinical Trials, Phase IV as Topic | Randomized Controlled Trials as Topic | Venous Thromboembolism - etiology | Pyrazoles - administration & dosage | Hemorrhage - chemically induced | Nonlinear Dynamics | Pyridones - adverse effects | Thromboembolism | Analysis | Hip joint | Anticoagulants | Decision making | Prophylaxis | Clinical trials | Safety | Bleeding
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 09/2015, Volume 13, Issue 9, pp. 1597 - 1605
Journal Article